Tests catheter ablation for atrial fibrillation in people with brain bleeding
Compares catheter ablation with usual care in adults with atrial fibrillation and brain bleeding.
Plain-language title generated from the registry record
Registry title: SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)
Key facts
- Where
- Beijing, Changchun, Harbin, Hefei, Xi’an, and Xiamen, ChinaSee the 7 sites
Where in China
- Beijing Anzhen Hospital, Capital Medical UniversityBeijing, ChinaTaking people
- The First Hospital of Jilin UniversityChangchun, ChinaNot yet recruiting
- The First Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNot yet recruiting
- The Second Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNot yet recruiting
- The First Affiliated Hospital of Anhui Medical UniversityHefei, ChinaNot yet recruiting
- The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, ChinaNot yet recruiting
- Xiamen Cadiovascular HospitalXiamen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Anzhen Hospital
- Trial code
- NCT07316270
- Record updated
- 7 August 2026
- Original description
SAFER-AF is an investigator-initiated, multicenter, open-label, parallel-group trial comparing catheter ablation versus usual care in patients with atrial fibrillation and intracranial hemorrhage.Read full original descriptionShow less
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)
SAFER-AF is an investigator-initiated, multicenter, open-label, parallel-group trial comparing catheter ablation versus usual care in patients with atrial fibrillation and intracranial hemorrhage.
Inclusion: Age ≥ 18 years; Between 14 Days and 12 Months After Spontaneous Intracranial Hemorrhage (intraparenchymal or intraventricular hemorrhage, and subdural hematoma); Able to Access Intracranial Hemorrhage Imaging Data; ECG indicating the presence of atrial fibrillation; CHA₂DS₂-VA Score ≥ 2; Willing to undergo randomization and able to complete follow-up as required.
Exclusion: End-stage renal failure or receiving dialysis treatment; Uncontrolled hypertension (systolic blood pressure > 160 mmHg); Presence of uncontrolled active bleeding; Presence of active infection requiring antibiotic treatment; Presence of liver failure; Untreated coronary artery disease with indication for revascularization; Expected life expectancy < 1 year (e.g., advanced malignant tumors, etc.); Presence of psychological or psychiatric disorders that prevent understanding or cooperation with the study; Other conditions deemed unsuitable for participation in the study by the investigators; Atrial fibrillation secondary to clearly reversible causes (e.g., hyperthyroidism, hypokalemia, etc.); Fully dependent (modified Rankin Scale [mRS] score > 4); Presence of intracardiac masses, thrombi, etc., as evaluated by transthoracic echocardiography or transesophageal echocardiography; Pregnant, lactating, or women planning to become pregnant.